{"DataElement":{"publicId":"5810391","version":"1","preferredName":"Nitrosourea Compound Administered Type","preferredDefinition":"A description of the nitrosourea compound that was administered.","longName":"2871734v1.0:2960473v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2871734","version":"1","preferredName":"Nitrosourea Compound Administered","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas._The act of having given something (e.g., a medication or test).","longName":"2871732v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2871732","version":"1","preferredName":"Nitrosourea Compound","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas.","longName":"C699","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6952C686-03A3-2CDE-E040-BB89AD434B6C","latestVersionIndicator":"Yes","beginDate":"2009-05-07","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-05-07","modifiedBy":"ONEDATA","dateModified":"2009-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6952C686-03B1-2CDE-E040-BB89AD434B6C","latestVersionIndicator":"Yes","beginDate":"2009-05-07","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-05-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2960473","version":"1","preferredName":"Nitrosourea Compound Type","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas._Type; a subdivision of a particular kind of thing.","longName":"NIT_CMP_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Carmustine","valueDescription":"Carmustine","ValueMeaning":{"publicId":"2567422","version":"1","preferredName":"Carmustine","longName":"2567422","preferredDefinition":"A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781A9DB0-12D5-EEF4-E040-BB89AD4369AF","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"Lomustine","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781A9DB0-12E9-EEF4-E040-BB89AD4369AF","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781A9DB0-12F3-EEF4-E040-BB89AD4369AF","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2960472","version":"1","preferredName":"Nitrosourea Compound Type","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas.:Type; a subdivision of a particular kind of thing.","longName":"C699:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-12B0-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-12C1-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"NYCHM","dateModified":"2012-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set – Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedSubstanceAdministration:negationIndicator","type":"HCT_BRIDG_5","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the nitrosourea comp","type":"Preferred Question Text","description":"What was the nitrosourea compound that was administered?","url":null,"context":"NHLBI"},{"name":"What was the type of nitrosourea administered?","type":"Alternate Question Text","description":"What was the type of nitrosourea administered?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EF501D2-2345-68CB-E053-F662850A6D0C","latestVersionIndicator":"Yes","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ALEYR","dateModified":"2019-04-13","changeDescription":"System generated def displayed as alt def. released 8/28/17; Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}